Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Baldeon
  SRCTN85216856		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
63/95 inconclusive 77%
Bennett-Guerrero
  NCT04344535		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
59/15 inconclusive -18% -23%
CCAP-2
  NCT04345289		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedlow
98/46 inconclusive 93%
CONTAIN COVID-19
  NCT04364737		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
468/473 inconclusive -12%
NCT04442191
  NCT04442191		 RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedlow
8/6 inconclusive -80%

COVID-19 mild to moderate meta-analysis

Libster
  NCT04479163		 RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
80/80 conclusif -45%

COVID-19 severe or critically meta-analysis

O’Donnell
  NCT04359810		 RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
150/73 inconclusive -48% 18%
PlasmAr
  NCT04344535		 RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
228/106 inconclusive -6% -17%
4 studies excluded by filtering options (4 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons